Top 12 Most Expensive Drugs in the US Healthcare Market

Pediatrics

Vygon Launched Nutrisafe2 System; Butterfly Net...

Vygon Launched Neonatal Safety in India with Groundbreaking Nutrisafe2 System  On March 15, 2024, Vygon, a leader in the production and marketing of specialized medical equipment, introduced N...

Mar 21, 2024

Top Most Expensive Drugs in the US Healthcare Market
Top 12 Most Expensive Drugs in the US Healthcare Market

Drug pricing is one of the hottest topics in the healthcare segment. Several arguments have been put forward by people, governments, healthcare companies, and other organizations in favor of and against expensive medicines. Some of the drugs are so expensive that they are nearly out of reach of the common people. H...

Find More
pharma-news-for-merck-pfizer-gilead-abbvie-lantern-polpharma
Merck’s Gefapixant; Pfizer’s Somatrogon; Gilead’s Viklury; AbbVie’s Skyrizi; Gilead’s Zydelig Approvals; Lantern’s LP-184; Polpharma to Acquire Advent

Merck’s Chronic Cough Med Gefapixant Receives A Red Flag From the FDA, Requests For More Data On 24th January 2022, Merck & Co. announced FDA rejection for its New Drug Application (NDA) of Gefapixant (experimental drug) for unexplained or chronic cough. FDA asked for additional information on the drug, rela...

Find More
recent-pharma-biotech-news-updates-for-cidara-jj-supernus-rain
Cidara Therapeutics and J&J’s USD 780M Deal; FDA’s Approval to Supernus’s ADHD drug; Rain Therapeutics USD 100M IPO; NMPA Approval to Antengene’s ATG-019 IND Application

Cidara Therapeutics Inks USD 780M Deal with J&J The share price of Cidara observed a sudden jump after the news of the collaboration of the company with J&J came. Cidara Therapeutics has announced a deal with Johnson & Johnson to develop and commercialize Cidara’s candidate CD388 to prevent and treat...

Find More

More Views & Analysis

Dravet Syndrome Market | Dravet Syndrome Pipeline
The Rarity Of Dravet Syndrome: Challenges, and Treatments

As per DelveInsight, the Dravet syndrome market size was estimated to be USD 79.1 Million in 2017, which is expected to increase at a significant CAGR during the study period (2017–2030) owing to rich Dravet syndrome pipeline, increasing incidence, and heightened R&D. Dravet Syndrome, earlier known as sever...

Find More

Batten Disease market
Batten Disease Market: Barriers and Growth Opportunities

Batten disease overview Batten disease, referred to as Neuronal Ceroid Lipofuscinosis (NCL), is a family of rare diseases and a debilitating autosomal recessive neurodegenerative lysosomal storage disorder caused by cellular accumulation of abnormal auto-fluorescent lipoproteins lipofuscin. Patients with Batt...

Find More

patent ductus arteriosus
Notizia

Abbott’s pea-sized implant for congenital heart defects gets FDA approval FDA approved Abbott for its Amplatzer Piccolo Occluder, the implant designed for premature babies. The device is used to treat patent ductus arteriosus (PDA), a life-threatening opening in the hearts of premature newborns and is a minimal...

Find More

transthyretin amyloidosis
Notizia

The interleukin-33 antibody of AnaptysBio passes midstage test in asthma The pipeline drug, etokimab of AnaptysBio, has positive data in a third indication that adds asthma to one of its triumphs. The US-based company gets another proof-of-concept study for the interleukin-33 (IL-33) inhibitor, because of phase 2a ...

Find More

Reckitt Acquired Mead Johnson; LabCorp’s acquisition; Ferring collaborates; J&J Licenses

Mead Johnson Acquired By Reckitt Benckiser for $16.6 Billion Mead Johnson Nutrition Company (MJN), the manufacturer of infant formula and nutritional supplements, has agreed to be acquired by Britain's Reckitt Benckiser Group plc in a deal that values the former's equity at $16.6 billion. Mead Johnson shareholders w...

Find More

ALCMI, ALCF and Scancell partner; Sun unloads Ohm Labs plants; Takeda and Ovid join; Guardant and MD Anderson collaborate; Glooko and Ascensia integrate

ALCMI, ALCF and Scancell partner to evaluate SCIB2 cancer vaccine for NSCLC The Addario Lung Cancer Medical Institute (ALCMI) and the Bonnie J. Addario Lung Cancer Foundation (ALCF) have collaborated with UK-based Scancell to assess SCIB2 cancer vaccine to treat patients with non-small-cell lung cancer (NSCLC). SCIB...

Find More

Anorexia Nervosa (AN) is a psychological condition that is characterized by an abnormally low weight.....

Find More

Xerostomia is a condition characterized by dry mouth, which is a result of a reduced or absent flow .....

Find More

Halitosis is an oral health problem caused by volatile molecules which are formed because of patholo.....

Find More

Cell therapies now are often recommended to treat cancer in several ways, out of which CAR T-cell th.....

Find More

Doctors and scientists have recognized that traditional, complementary and alternative therapies hav.....

Find More

With worldwide dissemination and now over 9 million cases and nearly 500,000 deaths recorded, the ef.....

Find More